Decision-theoretic designs for pre-phase II screening trials in oncology
Related Experiment Video
Updated: Oct 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
1Medical and Pharmaceutical Statistics Research Unit, The University of Reading, Earley Gate, UK. n.stallard@reading.ac.uk
Abstract:
A Bayesian decision-theoretic method is proposed for conducting small, randomized pre-phase II selection trials. The aim is to improve on the design of Thall and Estey (1993, Statistics in Medicine 12, 1197-1211). Designs are derived that optimize a gain function accounting for current and future patient gains, per-patient cost, and future treatment development cost. To reduce the computational burden associated with backward induction, myopic versions of the design that consider only one, two, or three future decisions at a time are also considered. The designs are compared in the context of a screening trial in acute myelogenous leukemia.
Related Concept Videos
Clinical Trials: Overview
Preclinical Development: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cancer Survival Analysis

